Condition: Advanced Solid Tumors · Sponsor: Jacobio Pharmaceuticals Co., Ltd.
This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors
This description comes directly from the study's public registry record.
Jacobio Pharmaceuticals · (781) 918-6670 · clinicaltrials@jacobiopharma.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Cleveland Clinic Foundation | Cleveland, Ohio, United States | Recruiting |
| Huntsman Cancer Institute | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06973564